Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images

BACKGROUND: Currently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB). According to NCCN guidelines, Programmed death-ligand 1 (PD-L1) expression status determined by immunohistochemistr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Mu, Wei, Jiang, Lei, Shi, Yu, Tunali, Ilke, Gray, Jhanelle E, Katsoulakis, Evangelia, Tian, Jie, Gillies, Robert J, Schabath, Matthew B
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2021
Témata:
Immunotherapy Biomarkers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211060/
https://ncbi.nlm.nih.gov/pubmed/34135101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002118
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky